- Home
- ESPR vs BGH Comparison
ESPR vs BGH Comparison
Compare ESPR & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- BGH
- Stock Information
- Founded
- ESPR 2008
- BGH 2012
- Country
- ESPR United States
- BGH United States
- Employees
- ESPR N/A
- BGH N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- BGH Investment Managers
- Sector
- ESPR Health Care
- BGH Finance
- Exchange
- ESPR Nasdaq
- BGH Nasdaq
- Market Cap
- ESPR 305.0M
- BGH 318.8M
- IPO Year
- ESPR 2013
- BGH N/A
- Fundamental
- Price
- ESPR $1.63
- BGH $15.30
- Analyst Decision
- ESPR Buy
- BGH
- Analyst Count
- ESPR 7
- BGH 0
- Target Price
- ESPR $6.36
- BGH N/A
- AVG Volume (30 Days)
- ESPR 4.5M
- BGH 61.5K
- Earning Date
- ESPR 03-04-2025
- BGH 01-01-0001
- Dividend Yield
- ESPR N/A
- BGH 10.06%
- EPS Growth
- ESPR N/A
- BGH N/A
- EPS
- ESPR N/A
- BGH N/A
- Revenue
- ESPR $332,314,000.00
- BGH N/A
- Revenue This Year
- ESPR $5.51
- BGH N/A
- Revenue Next Year
- ESPR $1.42
- BGH N/A
- P/E Ratio
- ESPR N/A
- BGH N/A
- Revenue Growth
- ESPR 185.66
- BGH N/A
- 52 Week Low
- ESPR $1.47
- BGH $11.92
- 52 Week High
- ESPR $3.94
- BGH $14.50
- Technical
- Relative Strength Index (RSI)
- ESPR 45.89
- BGH 39.87
- Support Level
- ESPR $1.47
- BGH $15.08
- Resistance Level
- ESPR $1.75
- BGH $15.37
- Average True Range (ATR)
- ESPR 0.11
- BGH 0.14
- MACD
- ESPR 0.03
- BGH 0.01
- Stochastic Oscillator
- ESPR 57.14
- BGH 56.41
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.